menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Oncopeptides Expands WODA Partnership To Africa And Eurasia

    GLOBENEWSWIRE

    Oncopeptides and Vector Pharma Announce Collab to Provide Pepaxti to Patients

    GLOBENEWSWIRE

    FDA formally pulls Oncopeptides` cancer drug after prolonged back-and-forth

    ENDPTS

    CDER challenges Oncopeptides’ appeal over Pepaxto withdrawal

    ENDPTS

    Oncopeptides provides update on Pepaxto US marketing authorization

    PRNEWSWIRE

    Oncopeptides` Pepaxti has been granted marketing authorization in the UK

    PRNEWSWIRE

    Oncopeptides says trial data good, but not enough to sway FDA

    FIERCEPHARMA

    Oncopeptides`s Pepaxti (melphalan flufenamide) Receives Approval in Europe

    EMA

    Oncopeptides phase 3 OCEAN study published in the Lancet Haematology

    PRNEWSWIRE

    Oncopeptides presents new melflufen data at ASH

    PRNEWSWIRE

    Oncopeptides withdraws Pepaxto® in US, scale down organization and focus on R&D

    PRNEWSWIRE

    FDA warns of myeloma drug Pepaxto`s death risk

    FIERCEPHARMA

    Oncopeptides AB: Phase 3 OCEAN study demonstrates that melflufen is at least

    PRNEWSWIRE

    FDA Approves Oncopeptides´ PEPAXTO® (melphalan flufenamide) for Patients

    PRNEWSWIRE

    Oncopeptides Submits a New Drug Application to the FDA for Accelerated Approval

    PRNEWSWIRE

    Oncopeptides Reinitiates Patient Enrollment to the Melflufen Clinical Program

    PRNEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.